Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Goodwill & Intangibles (2021 - 2023)

Historic Goodwill & Intangibles for NovaBay Pharmaceuticals (NBY) over the last 3 years, with Q4 2023 value amounting to $5.3 million.

  • NovaBay Pharmaceuticals' Goodwill & Intangibles fell 620.54% to $5.3 million in Q4 2023 from the same period last year, while for Dec 2023 it was $5.3 million, marking a year-over-year decrease of 620.54%. This contributed to the annual value of $5.3 million for FY2023, which is 620.54% down from last year.
  • As of Q4 2023, NovaBay Pharmaceuticals' Goodwill & Intangibles stood at $5.3 million, which was down 620.54% from $5.6 million recorded in Q3 2023.
  • In the past 5 years, NovaBay Pharmaceuticals' Goodwill & Intangibles ranged from a high of $9.8 million in Q4 2021 and a low of $5.3 million during Q4 2023
  • Its 3-year average for Goodwill & Intangibles is $7.4 million, with a median of $5.6 million in 2022.
  • As far as peak fluctuations go, NovaBay Pharmaceuticals' Goodwill & Intangibles crashed by 4270.54% in 2022, and later plummeted by 620.54% in 2023.
  • Over the past 3 years, NovaBay Pharmaceuticals' Goodwill & Intangibles (Quarter) stood at $9.8 million in 2021, then tumbled by 42.71% to $5.6 million in 2022, then decreased by 6.21% to $5.3 million in 2023.
  • Its last three reported values are $5.3 million in Q4 2023, $5.6 million for Q3 2023, and $5.6 million during Q2 2023.